Gut Reactions #3 – vedolizumab (a new treatment option)

September 7, 2015 0

The National Institute for Health and Care Excellence (NICE) recently issued guidelines for a new drug called vedolizumab as a treatment option for patients with ulcerative colitis (UC) or Crohn’s disease (CD).

This is a significant development because it is the first new type of biological treatment for UC and CD in a decade. Vedolizumab targets a specific protein involved in chronic inflammation that is found only in the intestine. As a result, treatment with vedolizumab may reduce inflammation of the intestine with less side effects and risks that other biological treatments.

Vedolizumab is now available on the NHS. If you would like to find out more about this treatment option, we recommend speaking with your doctor.

Leave a Reply

Your email address will not be published. Required fields are marked *

At West Kent Gastroenterology, we work hard to provide our patients with top-class care. You will enjoy friendly, fast and modern treatment by a highly experienced gastroenterologist. We carefully review patient satisfaction and feedback, and at West Kent Gastroenterology we are continuously making improvements to our services, ensuring the highest level of care possible.

Clinic Locations

Spire Hospital
Fordcombe Road, Tunbridge Wells, Kent, TN3 0RD

Sevenoaks Medical Centre
London Road, Sevenoaks, Kent, TN13 2JD


@dradamharris - 3 months

I am delighted to be reopening my weekly Gastro clinic in the City of London with . I can be found e…

@dradamharris - 8 months

Was pleased to organise and speak at the 3rd annual “Update in Medicine for GPs” event that took place on Saturday…

© 2021 West Kent Gastroenterology Ltd.

Designed and Developed By